Page 123 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1

dose-ranging trial. Lancet. 2016 Jul 123
2;388(10039):31-44.
42. Maselli DJ, Velez MI, Rogers L. Resli- eosinophilic and allergic asthma phenotype and therapeutic possibilities
zumab in the management of poor-
ly controlled asthma: the data so far. J
Asthma Allergy. 2016 Aug 31;9:155-62.
43. Buhl R, Humbert M, Bjermer L,
et al. Severe eosinophilic asthma: a
roadmap to consensus.Eur Respir
J. 2017 May 1;49(5):1700634. doi:
10.1183/13993003.00634-2017.
44. Sze E, Bhalla A, Nair P. Mechanisms
and therapeutic strategies for non-T2
asthma. Allergy. 2020 Feb;75(2):311-25.
45. Brusselle GG, Koppelman GH. Biolog-
ic therapies for severe asthma. N Engl J
Med. 2022 Jan 13;386(2):157-71.
46. Menzies-Gow A, Corren J, Bourdin A,
et al. Tezepelumab in adults and ad-
olescence with severe uncontrolled
asthma. N Engl J Med. 2021 May
13;384(19):1800-9.
47. Wechsler ME, Ruddy MK, Pavord
ID, et al. Efficacy and safety of itepe-
kimab in patients with moderate-to-se-
vere asthma. N Engl J Med. 2021 Oct
28;385(18):1656-68.
48. Kelsen SG, Agache IO, Soong W. As-
tegolimab (anti-ST2) efficacy and safe-
ty in adults with severe asthma:a rand-
omized clinical trial. J Allergy Clin Im-
munol. 2021 Sep;148(3):790-8.